{ "version": "2.2", "instance": { "hypd-20260331x10q.htm": { "nsprefix": "hypd", "nsuri": "http://www.eyenoviabio.com/20260331", "dts": { "schema": { "local": [ "hypd-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "hypd-20260331_cal.xml" ] }, "definitionLink": { "local": [ "hypd-20260331_def.xml" ] }, "labelLink": { "local": [ "hypd-20260331_lab.xml" ] }, "presentationLink": { "local": [ "hypd-20260331_pre.xml" ] }, "inline": { "local": [ "hypd-20260331x10q.htm" ] } }, "keyStandard": 223, "keyCustom": 144, "axisStandard": 21, "axisCustom": 0, "memberStandard": 25, "memberCustom": 46, "hidden": { "total": 12, "http://xbrl.sec.gov/dei/2025": 5, "http://fasb.org/us-gaap/2025": 3, "http://www.eyenoviabio.com/20260331": 4 }, "contextCount": 174, "entityCount": 1, "segmentCount": 73, "elementCount": 653, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 517, "http://xbrl.sec.gov/dei/2025": 29, "http://xbrl.sec.gov/ecd/2025": 4 }, "report": { "R1": { "role": "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets", "longName": "995200100 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:AssetsCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R3": { "role": "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_m2iO9-IYR02XqQkFXoI6PQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R4": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations", "longName": "995200200 - Statement - Condensed Statements of Operations", "shortName": "Condensed Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R5": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit", "longName": "995200300 - Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit)", "shortName": "Condensed Statements of Changes in Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tGE3iujfFEC0qXcXAxxJYg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tGE3iujfFEC0qXcXAxxJYg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "longName": "995200305 - Statement - Condensed Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)", "shortName": "Condensed Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:PreferredStockDividendRatePerDollarAmount", "unitRef": "Unit_Divide_USD_shares_m2iO9-IYR02XqQkFXoI6PQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:PreferredStockDividendRatePerDollarAmount", "unitRef": "Unit_Divide_USD_shares_m2iO9-IYR02XqQkFXoI6PQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "longName": "995200400 - Statement - Condensed Statements of Cash Flows", "shortName": "Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R8": { "role": "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation", "longName": "995210101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation", "shortName": "Business Organization, Nature of Operations and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlans", "longName": "995210201 - Disclosure - Management's Liquidity Plans", "shortName": "Management's Liquidity Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:LiquidityPlanDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:LiquidityPlanDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210301 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStock", "longName": "995210401 - Disclosure - Net Income (Loss) Per Share of Common Stock", "shortName": "Net Income (Loss) Per Share of Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995210501 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssets", "longName": "995210601 - Disclosure - Digital Assets", "shortName": "Digital Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:DigitalAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:DigitalAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995210701 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayable", "longName": "995210801 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:NotesPayableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:NotesPayableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210901 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.eyenoviabio.com/role/DisclosureIncomeTax", "longName": "995211001 - Disclosure - Income Tax", "shortName": "Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficit", "longName": "995211101 - Disclosure - Stockholders' Equity (Deficit)", "shortName": "Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.eyenoviabio.com/role/DisclosureSegmentReporting", "longName": "995211201 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.eyenoviabio.com/role/DisclosureSubsequentEvents", "longName": "995211301 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockTables", "longName": "99930403 - Disclosure - Net Income (Loss) Per Share of Common Stock (Tables)", "shortName": "Net Income (Loss) Per Share of Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "99930503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "hypd:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "hypd:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsTables", "longName": "99930603 - Disclosure - Digital Assets (Tables)", "shortName": "Digital Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:CryptoAssetActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:CryptoAssetActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableTables", "longName": "99930803 - Disclosure - Notes Payable (Tables)", "shortName": "Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:ScheduleOfNotesPayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:ScheduleOfNotesPayableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitTables", "longName": "99931103 - Disclosure - Stockholders' Equity (Deficit) (Tables)", "shortName": "Stockholders' Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.eyenoviabio.com/role/DisclosureSegmentReportingTables", "longName": "99931203 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails", "longName": "99940101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation (Details)", "shortName": "Business Organization, Nature of Operations and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": null, "uniqueAnchor": null }, "R33": { "role": "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "longName": "99940201 - Disclosure - Management's Liquidity Plans (Details)", "shortName": "Management's Liquidity Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:WorkingCapitalDeficit", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "hypd:LiquidityPlanDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R34": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "99940301 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:UsTreasuryBillSecurities", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails", "longName": "99940302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurement (Details)", "shortName": "Summary of Significant Accounting Policies - Fair Value Measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CryptoAssetFairValueNoncurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FeRifUnvg0eXKxpx5pWH-Q", "name": "us-gaap:DerivativeLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R36": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "longName": "99940303 - Disclosure - Summary of Significant Accounting Policies - HyperLend Private Pool Participation Agreement and Revenue-Sharing Agreement (Details)", "shortName": "Summary of Significant Accounting Policies - HyperLend Private Pool Participation Agreement and Revenue-Sharing Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_srt_CryptoAssetAxis_hypd_HyperlendTokensMember_us-gaap_TypeOfArrangementAxis_hypd_PartnershipAgreementMember_bawgUiU9tU6Ci0zvecKG9Q", "name": "hypd:CryptoAssetNumberOfUnitsReceived", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_srt_CryptoAssetAxis_hypd_HyperlendTokensMember_us-gaap_TypeOfArrangementAxis_hypd_PartnershipAgreementMember_bawgUiU9tU6Ci0zvecKG9Q", "name": "hypd:CryptoAssetNumberOfUnitsReceived", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails", "longName": "99940304 - Disclosure - Summary of Significant Accounting Policies - Digital Intangible Assets Receivable and Credit Loss Allowance (Details)", "shortName": "Summary of Significant Accounting Policies - Digital Intangible Assets Receivable and Credit Loss Allowance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:DigitalIntangibleAssetsReceivableAfterAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_hypd_HihypeLiquidStakingTokenMember_sh5UNBbb70Wav0HHMcxP0g", "name": "hypd:CryptoAssetsCollateral", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R38": { "role": "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "longName": "99940401 - Disclosure - Net Income (Loss) Per Share of Common Stock (Details)", "shortName": "Net Income (Loss) Per Share of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_m2iO9-IYR02XqQkFXoI6PQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_3_31_2025_g9PYGweOv0Kiz6D_0LqwNQ", "name": "us-gaap:DilutiveSecurities", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R39": { "role": "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails", "longName": "99940402 - Disclosure - Net Income (Loss) Per Share of Common Stock - Calculation of Weighted Average Dilutive Shares of Common Stock (Details)", "shortName": "Net Income (Loss) Per Share of Common Stock - Calculation of Weighted Average Dilutive Shares of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "99940501 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:PrepaidInsurance", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "hypd:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:PrepaidInsurance", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "hypd:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "longName": "99940601 - Disclosure - Digital Assets - Native Staking (Details)", "shortName": "Digital Assets - Native Staking (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:CryptoAssetNumberOfUnitsStaked", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hypd:DigitalAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_srt_CryptoAssetAxis_hypd_DigitalAssetsReceivableMember_8SIvGENqdkS4IDdsxsiSlQ", "name": "hypd:CryptoAssetNumberOfUnitsStaked", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hypd:DigitalAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R42": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "longName": "99940602 - Disclosure - Digital Assets - HyperLend Private Pool Participation Agreement and Revenue-Sharing Agreement (Details)", "shortName": "Digital Assets - HyperLend Private Pool Participation Agreement and Revenue-Sharing Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_TypeOfArrangementAxis_hypd_PrivatePoolParticipationAgreementMember_KvAgva4yW0KYS1SUIsHYgQ", "name": "hypd:FutureExpectedPayments", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "hypd:DigitalAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "longName": "99940603 - Disclosure - Digital Assets - Digital Assets Receivable (Details)", "shortName": "Digital Assets - Digital Assets Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:CryptoAssetsReceivableAfterUnamortizedNonrefundableUpfrontFeeAndAllowanceForCreditLossNonCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_srt_CryptoAssetAxis_hypd_DigitalAssetsReceivableMember_zrZE5Owd90ezbixCqkZFYQ", "name": "us-gaap:InterestIncomeOperating", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "hypd:DigitalAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R44": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "longName": "99940604 - Disclosure - Digital Assets - OTC HYPE Options (Details)", "shortName": "Digital Assets - OTC HYPE Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:DerivativeLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_srt_CryptoAssetAxis_hypd_HypeDigitalAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CallOptionMember_LHv6lDrtOUy0kv8dDIK3tA", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "hypd:DigitalAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R45": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "longName": "99940605 - Disclosure - Digital Assets - Hyperion Rysk Vault Shares (Details)", "shortName": "Digital Assets - Hyperion Rysk Vault Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_hypd_UsDollarPeggedStablecoinNativeToHyperliquidEcosystemMember_MHJwNxuHaEqkEIohaSutUA", "name": "hypd:CryptoAssetsRealizedGainLossOnExchange", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R46": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "longName": "99940606 - Disclosure - Digital Assets - Digital Intangible Assets Receivable (Details)", "shortName": "Digital Assets - Digital Intangible Assets Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:CryptoAssetsReceivableProvisionForCreditLoss", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_srt_CryptoAssetAxis_hypd_DigitalIntangibleAssetsReceivableMember_qZEz7BXZoUqyfuxbk3QRCQ", "name": "hypd:CryptoAssetsReceivableAfterUnamortizedNonrefundableUpfrontFeeAndAllowanceForCreditLossNonCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R47": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "longName": "99940607 - Disclosure - Digital Assets - Digital Asset Reconciliation (Details)", "shortName": "Digital Assets - Digital Asset Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZNpFPSYNCEeqXYZ4ryrVAQ", "name": "hypd:CryptoAssetsFairValue", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CryptoAssetActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZNpFPSYNCEeqXYZ4ryrVAQ", "name": "hypd:CryptoAssetsFairValue", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CryptoAssetActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "longName": "99940608 - Disclosure - Digital Assets - Digital Assets (Details)", "shortName": "Digital Assets - Digital Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CryptoAssetCost", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CryptoAssetHoldingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CryptoAssetCost", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CryptoAssetHoldingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "longName": "99940609 - Disclosure - Digital Assets - Digital Intangible Assets (Details)", "shortName": "Digital Assets - Digital Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:DividendsPayableCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:DividendsPayableCurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "longName": "99940801 - Disclosure - Notes Payable (Details)", "shortName": "Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:NotesPayableCurrentGross", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "hypd:ScheduleOfNotesPayableTableTextBlock", "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:NotesPayableCurrentGross", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "hypd:ScheduleOfNotesPayableTableTextBlock", "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails", "longName": "99940802 - Disclosure - Notes Payable - Avenue Loan maturities (Details)", "shortName": "Notes Payable - Avenue Loan maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_hypd_LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundLpAndAvenueVentureOpportunitiesFundLpIiMember_LM1Ui7qdgEOvVDK2VtlnDA", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_us-gaap_DebtInstrumentAxis_hypd_LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundLpAndAvenueVentureOpportunitiesFundLpIiMember_LM1Ui7qdgEOvVDK2VtlnDA", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails", "longName": "99940803 - Disclosure - Notes Payable - FIRST Insurance Funding Loan (Details)", "shortName": "Notes Payable - FIRST Insurance Funding Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_2_24_2026_us-gaap_DebtInstrumentAxis_hypd_FirstInsuranceFundingLoanMember_7jglWjw2hE2RaeU1M9L4Jw", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_2_24_2026_us-gaap_DebtInstrumentAxis_hypd_FirstInsuranceFundingLoanMember_7jglWjw2hE2RaeU1M9L4Jw", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "hypd:NotesPayableDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "longName": "99940901 - Disclosure - Commitments and Contingencies - Hype Asset Use Service Agreement (Details)", "shortName": "Commitments and Contingencies - Hype Asset Use Service Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CryptoAssetFairValueNoncurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_12_2025_srt_CounterpartyNameAxis_hypd_CredoCaymanMember_srt_CryptoAssetAxis_hypd_HypeDigitalAssetsMember_us-gaap_TypeOfArrangementAxis_hypd_HypeAssetUseServiceAgreementMember_NgbKvPkx9E-oeTJ4fRRQPg", "name": "hypd:CryptoAssetNumberOfUnitsLinkedToTradingWallet", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R55": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "longName": "99940902 - Disclosure - Commitments and Contingencies - HyperLend Revenue-Sharing Agreement (Details)", "shortName": "Commitments and Contingencies - HyperLend Revenue-Sharing Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:DigitalIntangibleAssetsReceivableAfterAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_srt_CryptoAssetAxis_hypd_HypeDigitalAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CallOptionMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_hypd_LiquidStakingTokenMember_cGTYVEp4S0CZxdOppPQaPg", "name": "hypd:CryptoAssetsCollateral", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R56": { "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "longName": "99940903 - Disclosure - Commitments and Contingencies - Joint Validator Operators' Agreement (Details)", "shortName": "Commitments and Contingencies - Joint Validator Operators' Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CryptoAssetFairValueNoncurrent", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_27_2025_To_10_27_2025_srt_CounterpartyNameAxis_hypd_KinetiqResearchPteAndPierTwoPtyLtdMember_R5V7A6LhYkSXSC9nIf9WFw", "name": "hypd:CryptoAssetNumberOfUnitsInitiatedForStake", "unitRef": "Unit_Standard_item_nyNaUmscJUGRWJ22BKpzxA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R57": { "role": "http://www.eyenoviabio.com/role/DisclosureIncomeTaxDetails", "longName": "99941001 - Disclosure - Income Tax (Details)", "shortName": "Income Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_KYuJzAWDdEWfhKxy3cWOew", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_KYuJzAWDdEWfhKxy3cWOew", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAuthorizedCapitalDetails", "longName": "99941101 - Disclosure - Stockholders' Equity (Deficit) - Authorized Capital (Details)", "shortName": "Stockholders' Equity (Deficit) - Authorized Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:NumberOfVotesPerCommonShare", "unitRef": "Unit_Standard_Vote_3e8kvUkRak2xBz1sRuCr4g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R59": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "longName": "99941102 - Disclosure - Stockholders' Equity (Deficit) - Common Stock Issuances (Details)", "shortName": "Stockholders' Equity (Deficit) - Common Stock Issuances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_6_20_2025_To_6_20_2025_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_0vY1UHlzIEuHZ2hlMfXPbA", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_5_2026_To_1_5_2026_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5P1uqTzD-0qmoHeI7Xqs2w", "name": "us-gaap:PreferredStockDividendsShares", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R60": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "longName": "99941103 - Disclosure - Stockholders' Equity (Deficit) - At-The-Market Program (Details)", "shortName": "Stockholders' Equity (Deficit) - At-The-Market Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_SubsidiarySaleOfStockAxis_hypd_AtMarketOfferingProgramMember_is_Q3aUTtUuyoa26lLNl1A", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_SubsidiarySaleOfStockAxis_hypd_AtMarketOfferingProgramMember_is_Q3aUTtUuyoa26lLNl1A", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "longName": "99941104 - Disclosure - Stockholders' Equity (Deficit) - Series A Preferred Stock Securities Purchase Agreements (Details)", "shortName": "Stockholders' Equity (Deficit) - Series A Preferred Stock Securities Purchase Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_m2iO9-IYR02XqQkFXoI6PQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_20_2025_us-gaap_ClassOfWarrantOrRightAxis_hypd_InvestorWarrantsMember_gtQGshpj-E-Jp3HnOOpQCw", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R62": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails", "longName": "99941105 - Disclosure - Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)", "shortName": "Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails", "longName": "99941106 - Disclosure - Stockholders' Equity (Deficit) - Warrants (Details)", "shortName": "Stockholders' Equity (Deficit) - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:ClassOfWarrantOrRightIssued", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "hypd:ClassOfWarrantOrRightExercised", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:ClassOfWarrantOrRightIssued", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "hypd:ClassOfWarrantOrRightExercised", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails", "longName": "99941107 - Disclosure - Stockholders' Equity (Deficit) - Restricted stock units activity (Details)", "shortName": "Stockholders' Equity (Deficit) - Restricted stock units activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ZNpFPSYNCEeqXYZ4ryrVAQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ZNpFPSYNCEeqXYZ4ryrVAQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "longName": "99941108 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details)", "shortName": "Stockholders' Equity (Deficit) - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_12_29_2025_To_12_29_2025_3zJhHdDhO0C2kffrvOJimQ", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_12_29_2025_To_12_29_2025_3zJhHdDhO0C2kffrvOJimQ", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Unit_Standard_shares_tvGUIAIQo024qK7uriMwOg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.eyenoviabio.com/role/DisclosureSegmentReportingDetails", "longName": "99941201 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_JHMsAEmH70uj1PL7Z8mK4w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_JHMsAEmH70uj1PL7Z8mK4w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "longName": "99941202 - Disclosure - Segment Reporting - Significant expenses (Details)", "shortName": "Segment Reporting - Significant expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "hypd:ResearchAndDevelopmentExpenseSalariesAndBenefits", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R68": { "role": "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "longName": "99941203 - Disclosure - Segment Reporting - Segment assets (Details)", "shortName": "Segment Reporting - Segment assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "us-gaap:CryptoAssetFairValue", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } }, "R69": { "role": "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "longName": "99941301 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_3_31_2026_muh0Yj92rkSd9o3FbYq36w", "name": "us-gaap:CryptoAssetPurchase", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:CryptoAssetActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2026_6K-kQxfFhkSvtdP_2lYCwg", "name": "hypd:CryptoAssetsInConnectionWithHausAgreement", "unitRef": "Unit_Standard_USD_tfBxQyEd9k2Eunxa3h8SKA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hypd-20260331x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "hypd_AccountingPoliciesDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AccountingPoliciesDisclosureLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounting Policies Disclosure [Line Items]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "hypd_AccountingPoliciesDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AccountingPoliciesDisclosureTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to accounting policies in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Accounting Policies Disclosure [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "verboseLabel": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r354" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r696" ] }, "hypd_AccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "hypd_AccruedFranchiseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AccruedFranchiseTax", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for franchise taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Franchise Tax", "terseLabel": "Accrued franchise tax" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Unpaid costs", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "hypd_AccruedReworkOfClinicalSupplyReturnsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AccruedReworkOfClinicalSupplyReturnsCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued rework of clinical supply returns current.", "label": "Accrued Rework of Clinical Supply Returns, Current", "terseLabel": "Accrued rework of clinical supply returns" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r748" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r40", "r696", "r975" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r527", "r828", "r829", "r830", "r831", "r910", "r978" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r761" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r761" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r761" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r761" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings", "negatedLabel": "Preferred stock dividend ($xx per preferred share outstanding)", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance." } } }, "auth_ref": [ "r5", "r60" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Amortization of restricted stock units", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement." } } }, "auth_ref": [ "r868", "r870" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Amortization of stock option awards", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [ "r868", "r870" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition [Abstract]", "terseLabel": "Stock-based compensation:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r319" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Warrant modification and additional warrants-in issuance costs for inducement", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r5", "r60" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Split", "negatedLabel": "Reverse stock split settlement of fractional shares", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": [ "r5", "r60" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrant modification and additional warrants - incremental value", "verboseLabel": "Warrant modification and additional warrants - incremental value", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r5", "r23", "r60" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r794" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r720", "r730", "r740", "r772" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r723", "r733", "r743", "r775" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r795" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r761" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r768" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r724", "r734", "r744", "r768", "r776", "r780", "r788" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r786" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r347", "r351", "r352" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "hypd_AmortizationOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AmortizationOfDebtDiscount", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of Amortization of debt discount.", "label": "Amortization of Debt Discount", "terseLabel": "Amortization of debt discount" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r3", "r50", "r270", "r929" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r155" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r155" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Income (Loss) Per Share of Common Stock", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r155" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r155" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r384" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r65", "r74", "r91", "r111", "r114", "r115", "r159", "r171", "r189", "r193", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r385", "r387", "r447", "r478", "r479", "r487", "r564", "r651", "r652", "r665", "r696", "r699", "r700", "r711", "r863", "r864", "r931" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total Current Assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r87", "r96", "r111", "r114", "r115", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r385", "r387", "r447", "r696", "r863", "r864", "r931" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current Assets" } } }, "auth_ref": [] }, "hypd_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "documentation": "At Market Offering [Member]", "label": "At Market Offering", "terseLabel": "At Market Offering" } } }, "auth_ref": [] }, "hypd_AtMarketOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AtMarketOfferingProgramMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to at-the-market offering program.", "label": "At Market Offering Program", "terseLabel": "At-The-Market Program" } } }, "auth_ref": [] }, "hypd_AvenueNotePayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "AvenueNotePayableMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Avenue - Note payable.", "label": "Avenue - Note Payable [Member]", "terseLabel": "Avenue - Note payable" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r783" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r784" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r779" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r779" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r779" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r779" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r779" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r779" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r782" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r781" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r780" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r780" ] }, "us-gaap_CallOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CallOptionMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Call Option [Member]", "terseLabel": "Call option", "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option." } } }, "auth_ref": [ "r603", "r604" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Values", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r444", "r445", "r446", "r629", "r925" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r8", "r89", "r631" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r9", "r63" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents - End of Period", "periodStartLabel": "Cash and Cash Equivalents - Beginning of Period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r8", "r53", "r108" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase in Cash and Cash Equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r53" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r759" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r756" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r754" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r78", "r92", "r93", "r94", "r111", "r115", "r142", "r146", "r150", "r154", "r161", "r162", "r201", "r244", "r247", "r248", "r249", "r253", "r254", "r276", "r277", "r279", "r280", "r282", "r284", "r287", "r288", "r292", "r295", "r301", "r447", "r521", "r522", "r523", "r524", "r527", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r552", "r572", "r591", "r615", "r616", "r617", "r618", "r619", "r798", "r823", "r825", "r832" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r869" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "hypd_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercisable.", "label": "Class of Warrant or Right, Exercisable", "verboseLabel": "Warrants Exercisable, Exercisable Number of Warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants Outstanding, Exercise price", "verboseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r111", "r117", "r302" ] }, "hypd_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ClassOfWarrantOrRightExercised", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period.", "label": "Class of Warrant or Right, Exercised", "negatedLabel": "Exercised" } } }, "auth_ref": [] }, "hypd_ClassOfWarrantOrRightExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ClassOfWarrantOrRightExpired", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights expired during the period.", "label": "Class Of Warrant Or Right Expired", "terseLabel": "Expired" } } }, "auth_ref": [] }, "hypd_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued during the period.", "label": "Class Of Warrant Or Right Issued", "terseLabel": "Issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "verboseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "No of common stock per warrant", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r302" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "Warrants Outstanding, Outstanding Number of Warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r869" ] }, "hypd_ClassOfWarrantOrRightWeightedAverageRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingLife", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average remaining period of class of warrants or rights.", "label": "Class of Warrant or Right, Weighted Average Remaining Life", "terseLabel": "Warrants Exercisable, Weighted Average Remaining Life In Years" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r760" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r760" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r36", "r68", "r488", "r551" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r57", "r236", "r237", "r625", "r855", "r860" ] }, "us-gaap_CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockDividendsShares", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock Dividends, Shares", "terseLabel": "Issuance of common stock for payment in kind of preferred stock dividend (in shares)", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r5" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r701", "r702", "r703", "r705", "r706", "r707", "r708", "r828", "r829", "r831", "r910", "r974", "r978" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAuthorizedCapitalDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAuthorizedCapitalDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r39", "r552" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r39", "r552", "r570", "r978", "r979" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.0001 par value, 600,000,000 shares authorized; 11,428,482 shares issued and outstanding as of March 31, 2026;8,762,329 shares issued and 8,680,005 shares outstanding as of December 31, 2025, respectively", "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares." } } }, "auth_ref": [ "r39", "r552" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r765" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r764" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r766" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r763" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r72", "r111", "r112", "r118", "r121", "r159", "r173", "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r481", "r651", "r652", "r863", "r864" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r72", "r111", "r112", "r118", "r121", "r159", "r173", "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r481", "r651", "r652", "r863", "r864" ] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Amount Issued", "terseLabel": "Common stock issued upon conversion of preferred stock", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r10", "r11", "r12" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of stock, Preferred stock converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r10", "r11", "r12" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversion of stock, common stock issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r10", "r11", "r12" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "verboseLabel": "Convertible debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r58", "r255", "r256", "r261", "r262", "r263", "r266", "r267", "r268", "r269", "r270", "r660", "r661", "r662", "r663", "r664" ] }, "hypd_CorporateAndReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CorporateAndReconcilingItemsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to corporate and reconciling items.", "label": "Corporate and Reconciling Items [Member]", "terseLabel": "Corporate / Other" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "negatedLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r46", "r111", "r114", "r115", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r447", "r651", "r863" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r111", "r119", "r120", "r258", "r290", "r465", "r474", "r485", "r634", "r635", "r636", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r906", "r907", "r908", "r909" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "hypd_CredoCaymanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CredoCaymanMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Credo Cayman.", "label": "Credo Cayman [Member]", "terseLabel": "Credo Cayman" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetActivityLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Activity [Line Items]", "terseLabel": "Digital Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r844", "r847", "r848", "r849", "r850", "r851" ] }, "us-gaap_CryptoAssetActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetActivityTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Activity [Table]", "documentation": "Disclosure of information about activity for crypto asset. Excludes information about crypto asset held for platform user." } } }, "auth_ref": [ "r847", "r848", "r849", "r850", "r851" ] }, "us-gaap_CryptoAssetActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetActivityTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsTables" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Activity [Table Text Block]", "terseLabel": "Schedule of digital asset reconciliation", "documentation": "Tabular disclosure of information about activity for crypto asset. Excludes information about crypto asset held for platform user." } } }, "auth_ref": [ "r847" ] }, "hypd_CryptoAssetAndCryptoAssetReceivableRealizedGainLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetAndCryptoAssetReceivableRealizedGainLossOperating", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from remeasurement of crypto asset and crypto asset receivable, classified as operating. Excludes crypto asset held for platform user.", "label": "Crypto Asset and Crypto Asset Receivable, Realized Gain (Loss), Operating", "negatedLabel": "Realized gain - digital assets and digital assets receivable" } } }, "auth_ref": [] }, "srt_CryptoAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CryptoAssetAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset [Axis]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r224", "r231", "r844", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "hypd_CryptoAssetCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetCommissionExpense", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of commission paid in connection with crypto asset transactions during the reporting period.", "label": "Crypto Asset, Commission Expense", "negatedLabel": "HYPE commission paid to co-validators", "terseLabel": "HYPE commission paid to co-validators" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetCost", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Cost", "terseLabel": "Digital Assets, Cost Basis", "documentation": "Cost of crypto asset. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r220", "r222" ] }, "hypd_CryptoAssetDeposited": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetDeposited", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in crypto asset resulting from deposit of crypto assets for exchange.", "label": "Crypto Asset, Deposited", "terseLabel": "Company deposited", "verboseLabel": "Deposits of USDH into Hyperion Rysk Vault" } } }, "auth_ref": [] }, "hypd_CryptoAssetDispositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetDispositions", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in crypto asset from disposition. Excludes crypto asset held for platform user.", "label": "Crypto Asset, Dispositions", "terseLabel": "Deposits of HYPE into liquid staking activities", "verboseLabel": "Deposits of digital assets into liquid staking activities" } } }, "auth_ref": [] }, "srt_CryptoAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CryptoAssetDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset [Domain]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r224", "r231", "r844", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854" ] }, "hypd_CryptoAssetExchangeOfDigitalIntangibleAssetsReceivableForDigitalIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetExchangeOfDigitalIntangibleAssetsReceivableForDigitalIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in crypto asset resulting from exchange of digital intangible assets receivable for digital intangible assets.", "label": "Crypto Asset, Exchange of Digital Intangible Assets Receivable for Digital Intangible Assets", "terseLabel": "Exchange of digital intangible assets receivable for digital intangible assets" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetFairValue", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Fair Value", "terseLabel": "Digital assets", "documentation": "Fair value of crypto asset. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r219", "r220", "r223", "r225" ] }, "us-gaap_CryptoAssetFairValueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetFairValueNoncurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Fair Value, Noncurrent", "verboseLabel": "Digital assets", "documentation": "Fair value of crypto asset classified as noncurrent. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r219", "r220", "r223", "r225" ] }, "us-gaap_CryptoAssetHoldingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetHoldingLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Holding [Line Items]", "terseLabel": "Digital Assets", "verboseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r224" ] }, "us-gaap_CryptoAssetHoldingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetHoldingTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Holding [Table]", "documentation": "Disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user." } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r224" ] }, "us-gaap_CryptoAssetHoldingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetHoldingTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsTables" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Holding [Table Text Block]", "terseLabel": "Schedule of digital assets", "documentation": "Tabular disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user." } } }, "auth_ref": [ "r846" ] }, "hypd_CryptoAssetHypeAssetUseServiceAgreementAutomaticRenewable": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetHypeAssetUseServiceAgreementAutomaticRenewable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Automatic renewable for which the Hype asset use service agreement is being entered into for joint operations, validations and attestation of the blocks and consensus protocol of the digital assets, expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Hype Asset Use Service Agreement, Automatic Renewable", "terseLabel": "HAUS Agreement automatic renewable periods" } } }, "auth_ref": [] }, "hypd_CryptoAssetHypeAssetUseServiceAgreementInitialTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetHypeAssetUseServiceAgreementInitialTerm", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial period for which the Hype asset use service agreement is being entered into for joint operations, validations and attestation of the blocks and consensus protocol of the digital assets, expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Hype Asset Use Service Agreement, Initial Term", "terseLabel": "HAUS Agreement initial term" } } }, "auth_ref": [] }, "hypd_CryptoAssetHypeAssetUseServiceAgreementTerminatedNotice": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetHypeAssetUseServiceAgreementTerminatedNotice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Terminated notice for which the Hype asset use service agreement is being entered into for joint operations, validations and attestation of the blocks and consensus protocol of the digital assets, expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Hype Asset Use Service Agreement, Terminated Notice", "verboseLabel": "HAUS Agreement terminated notice period" } } }, "auth_ref": [] }, "hypd_CryptoAssetHypeAssetUseServiceAgreementThresholdPriorWrittenNoticePeriodForTermination": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetHypeAssetUseServiceAgreementThresholdPriorWrittenNoticePeriodForTermination", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold written notice period for termination Hype asset use service agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Hype Asset Use Service Agreement, Threshold Prior Written Notice Period For Termination", "terseLabel": "Threshold prior written notice period for termination" } } }, "auth_ref": [] }, "hypd_CryptoAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetImpairment", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of impairment on crypto assets", "label": "Crypto Asset, Impairment", "negatedLabel": "Impairment" } } }, "auth_ref": [] }, "hypd_CryptoAssetJointValidatorAgreementInitialTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetJointValidatorAgreementInitialTerm", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial period for which the joint validator agreement is being entered into for joint operations, validations and attestation of the blocks and consensus protocol of the digital assets, expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Joint Validator Agreement, Initial Term", "terseLabel": "Joint validator agreement" } } }, "auth_ref": [] }, "hypd_CryptoAssetJointValidatorAgreementThresholdPriorNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetJointValidatorAgreementThresholdPriorNoticePeriod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold period of prior notice to serve by the party to the joint validator agreement to terminate the contract expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Joint Validator Agreement, Threshold Prior Notice Period", "terseLabel": "Notice period of agreement" } } }, "auth_ref": [] }, "hypd_CryptoAssetLiquidStakingActivityVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetLiquidStakingActivityVestingPeriod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the time period during which liquid staking rewards are vested for a crypto asset.", "label": "Crypto Asset, Liquid Staking Activity, Vesting Period", "terseLabel": "Time period during which liquid staking rewards are vested for a crypto asset" } } }, "auth_ref": [] }, "hypd_CryptoAssetNetAmountReceivedFromNativeStakingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNetAmountReceivedFromNativeStakingActivities", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in crypto asset as a result of net amount received from native staking activities.", "label": "Crypto Asset, Net Amount Received From Native Staking Activities", "terseLabel": "Net HYPE received from native staking activities" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfNativeUnitsStaked": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfNativeUnitsStaked", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of native crypto asset units staked.", "label": "Crypto Asset, Number Of Native Units Staked", "terseLabel": "Number of native units staked" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetNumberOfUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetNumberOfUnits", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Number of Units", "terseLabel": "Digital Assets, Units", "documentation": "Number of restricted and unrestricted crypto asset units held. Excludes crypto asset units held for platform user." } } }, "auth_ref": [ "r224" ] }, "hypd_CryptoAssetNumberOfUnitsAllocatedToMultiSignatureWallet": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsAllocatedToMultiSignatureWallet", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units allocated to a multi-signature wallet.", "label": "Crypto Asset, Number Of Units Allocated To Multi Signature Wallet", "terseLabel": "Number of units allocated to a multi-signature wallet" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsInitiatedForStake": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsInitiatedForStake", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of units of crypto asset initiated for stake by the entity under the joint validator agreement.", "label": "Crypto Asset, Number Of Units Initiated For Stake", "terseLabel": "Number of units initiated for stake" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsLinkedToTradingWallet": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsLinkedToTradingWallet", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units linked to trading wallet.", "label": "Crypto Asset, Number Of Units Linked To Trading Wallet", "terseLabel": "Number of units linked to trading wallet" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsPurchased": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsPurchased", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units purchased during the period.", "label": "Crypto Asset, Number of Units, Purchased", "terseLabel": "Number of units purchased" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsReceived": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsReceived", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Private Pool Participation Agreement.", "label": "Crypto Asset, Number of Units Received", "terseLabel": "Number of units received" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsReturned": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsReturned", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units returned.", "label": "Crypto Asset, Number of Units Returned", "terseLabel": "Number of units returned" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsRewardEarned": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsRewardEarned", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units on which staking reward has been earned.", "label": "Crypto Asset, Number of Units, Reward Earned", "terseLabel": "Number of units of reward earned" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsStaked": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsStaked", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units staked by the entity.", "label": "Crypto Asset, Number of Units, Staked", "terseLabel": "Number of units staked" } } }, "auth_ref": [] }, "hypd_CryptoAssetNumberOfUnitsToBeStaked": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetNumberOfUnitsToBeStaked", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of units of crypto asset to be staked.", "label": "Crypto asset, Number of Units to Be Staked", "terseLabel": "Number of units of crypto asset to be staked" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetPurchase", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Purchase", "terseLabel": "Purchase of crypto asset", "verboseLabel": "HYPE Purchases", "documentation": "Amount of increase in crypto asset from purchase. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r848" ] }, "hypd_CryptoAssetPurchasedFromLiquidStaking": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetPurchasedFromLiquidStaking", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in crpto asset resulting from purchases through liquid staking activities during the reporting period.", "label": "Crypto Asset, Purchased From Liquid Staking", "terseLabel": "Receipts of digital assets from liquid staking activities" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetRealizedAndUnrealizedGainOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetRealizedAndUnrealizedGainOperating", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Realized and Unrealized Gain, Operating", "terseLabel": "Realized and unrealized gains", "documentation": "Amount of realized and unrealized gain from remeasurement of crypto asset, classified as operating. Excludes change for crypto asset held for platform user." } } }, "auth_ref": [ "r226", "r845" ] }, "us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetRealizedAndUnrealizedLossOperating", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Realized and Unrealized Loss, Operating", "negatedLabel": "Realized and unrealized losses", "documentation": "Amount of realized and unrealized loss from remeasurement of crypto asset, classified as operating. Excludes change for crypto asset held for platform user." } } }, "auth_ref": [ "r227", "r845" ] }, "us-gaap_CryptoAssetRealizedGainLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetRealizedGainLossOperating", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Realized Gain (Loss), Operating", "negatedLabel": "Realized gain - digital assets", "documentation": "Amount of realized gain (loss) from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r845" ] }, "us-gaap_CryptoAssetRealizedGainOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetRealizedGainOperating", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Realized Gain, Operating", "verboseLabel": "Realized gain", "documentation": "Amount of realized gain from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r850" ] }, "us-gaap_CryptoAssetRealizedLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetRealizedLossOperating", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Realized Loss, Operating", "terseLabel": "Realized loss", "documentation": "Amount of realized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r851" ] }, "hypd_CryptoAssetReceiptFromPartnershipAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetReceiptFromPartnershipAgreement", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in crypto asset resulting from receipt of crypto assets from partnership agreements.", "label": "Crypto Asset, Receipt From Partnership Agreement", "terseLabel": "Receipt of HPL pursuant to partnership agreement" } } }, "auth_ref": [] }, "hypd_CryptoAssetReceivableUnrealizedGainLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetReceivableUnrealizedGainLossOperating", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) from remeasurement of crypto asset receivable, classified as operating. Excludes crypto asset held for platform user.", "label": "Crypto Asset Receivable, Unrealized Gain (Loss), Operating", "negatedLabel": "Unrealized gain - digital intangible assets receivable" } } }, "auth_ref": [] }, "hypd_CryptoAssetRedemption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetRedemption", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in crypto asset resulting from redemption.", "label": "Crypto Asset, Redemption", "terseLabel": "Impaired to USDH", "verboseLabel": "Redemption of WHYPE-USDH-USDH-P-H-HL from Hyperion Rysk Vault" } } }, "auth_ref": [] }, "hypd_CryptoAssetRestrictedNumberOfUnitsFreeTransferable": { "xbrltype": "perUnitItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetRestrictedNumberOfUnitsFreeTransferable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of restricted units of crypto assets free transferable on first day of each calendar month.", "label": "Crypto Asset, Restricted Number of Units Free Transferable", "terseLabel": "Number of restricted units of crypto assets free transferable" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetRollForward", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset [Roll Forward]", "verboseLabel": "Reconciliation of Company's assets and (liabilities) related to its digital assets", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "hypd_CryptoAssetSaleRestrictionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetSaleRestrictionTerm", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the period during which there is restriction on sale of crypto assets.", "label": "Crypto Asset, Sale Restriction Term", "terseLabel": "Sale restriction term" } } }, "auth_ref": [] }, "hypd_CryptoAssetStakingAndVestingConditionsPenaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetStakingAndVestingConditionsPenaltyPercentage", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of penalty payable when staking and vesting conditions are not met.", "label": "Crypto Asset, Staking and Vesting Conditions, Penalty Percentage", "terseLabel": "Percentage of penalty payable when staking and vesting conditions are not met" } } }, "auth_ref": [] }, "hypd_CryptoAssetStakingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetStakingIncome", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income earned from staking tokens, a virtual digital asset (VDA), on a block chain network or platform that supports staking.", "label": "Crypto Asset, Staking Income", "verboseLabel": "Staking income" } } }, "auth_ref": [] }, "hypd_CryptoAssetTemporaryUseAgreementAdditionalExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetTemporaryUseAgreementAdditionalExtensionTerm", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional extension period for which the crypto asset temporary use agreement is being extended, expressed in PnYnMnDTnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Temporary Use Agreement, Additional Extension Term", "terseLabel": "Temporary use agreement, additional extension term" } } }, "auth_ref": [] }, "hypd_CryptoAssetTemporaryUseAgreementAutomaticRenewable": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetTemporaryUseAgreementAutomaticRenewable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Automatic renewable term crypto asset in temporary use agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Temporary Use Agreement, Automatic Renewable", "terseLabel": "Temporary use agreement, automatic renewable" } } }, "auth_ref": [] }, "hypd_CryptoAssetTemporaryUseAgreementInitialTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetTemporaryUseAgreementInitialTerm", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial period for which the temporary use service agreement is being entered, expressed in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Temporary Use Agreement, Initial Term", "terseLabel": "Temporary use agreement, initial term" } } }, "auth_ref": [] }, "hypd_CryptoAssetTemporaryUseAgreementThresholdNoticePeriodForNonRenewal": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetTemporaryUseAgreementThresholdNoticePeriodForNonRenewal", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold notice period for non-renewal in temporary use agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Crypto Asset, Temporary Use Agreement, Threshold Notice Period For Non Renewal", "terseLabel": "Temporary use agreement, threshold notice of nonrenewal" } } }, "auth_ref": [] }, "hypd_CryptoAssetThresholdTermForStaking": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetThresholdTermForStaking", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period for staking crypto asset.", "label": "Crypto Asset, Threshold Term for Staking", "terseLabel": "Threshold period for staking crypto asset" } } }, "auth_ref": [] }, "us-gaap_CryptoAssetUnrealizedGainLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetUnrealizedGainLossOperating", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 3.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Unrealized Gain (Loss), Operating", "negatedLabel": "Unrealized gain - digital assets", "documentation": "Amount of unrealized gain (loss) from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r845" ] }, "us-gaap_CryptoAssetUnrealizedGainOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetUnrealizedGainOperating", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Unrealized Gain, Operating", "terseLabel": "Unrealized gain", "documentation": "Amount of unrealized gain from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r850" ] }, "us-gaap_CryptoAssetUnrealizedLossOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CryptoAssetUnrealizedLossOperating", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Crypto Asset, Unrealized Loss, Operating", "terseLabel": "Unrealized loss", "documentation": "Amount of unrealized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r851" ] }, "hypd_CryptoAssetUnstakingQuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetUnstakingQuePeriod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of unstaking que for crypto assets.", "label": "Crypto Asset, Unstaking Que Period", "terseLabel": "Number of days in unstaking que" } } }, "auth_ref": [] }, "hypd_CryptoAssetValueOfUnitsAvailable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetValueOfUnitsAvailable", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of crypto asset units available.", "label": "Crypto Asset, Value of Units Available", "terseLabel": "Tokens available" } } }, "auth_ref": [] }, "hypd_CryptoAssetValueOfUnitsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetValueOfUnitsReceived", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of crypto asset units received.", "label": "Crypto Asset, Value of Units Received", "terseLabel": "Tokens valued" } } }, "auth_ref": [] }, "hypd_CryptoAssetsCollateral": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsCollateral", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of crypto assets given as collateral.", "label": "Crypto Assets, Collateral", "terseLabel": "Number of crypto assets given as collateral" } } }, "auth_ref": [] }, "hypd_CryptoAssetsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsFairValue", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of crypto asset. Excludes crypto asset held for platform user.", "label": "Crypto Assets, Fair Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "auth_ref": [] }, "hypd_CryptoAssetsInConnectionWithHausAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsInConnectionWithHausAgreement", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of crypto assets HYPE digital assets in connection with HAUS Agreements.", "label": "Crypto Assets In Connection With HAUS Agreement", "terseLabel": "HYPE digital assets" } } }, "auth_ref": [] }, "hypd_CryptoAssetsNonCashInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsNonCashInterestIncome", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash interest income from crypto assets.", "label": "Crypto Assets, Non Cash Interest Income", "terseLabel": "Non-cash interest income from digital assets receivable" } } }, "auth_ref": [] }, "hypd_CryptoAssetsNumberOfUnitsRedeemed": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsNumberOfUnitsRedeemed", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of crypto asset units redeemed during the period.", "label": "Crypto Assets, Number Of Units Redeemed", "terseLabel": "Number of units redeemed" } } }, "auth_ref": [] }, "hypd_CryptoAssetsRealizedGainLossOnExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsRealizedGainLossOnExchange", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on exchange of crypto assets.", "label": "Crypto Assets, Realized Gain (Loss) On Exchange", "terseLabel": "Realized gain (loss) on exchange" } } }, "auth_ref": [] }, "hypd_CryptoAssetsRealizedGainLossOnRedemption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsRealizedGainLossOnRedemption", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on redemption of crypto assets.", "label": "Crypto Assets, Realized Gain (Loss) On Redemption", "terseLabel": "Realized gain (loss)" } } }, "auth_ref": [] }, "hypd_CryptoAssetsReceivableAfterUnamortizedNonrefundableUpfrontFeeAndAllowanceForCreditLossNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsReceivableAfterUnamortizedNonrefundableUpfrontFeeAndAllowanceForCreditLossNonCurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized nonrefundable upfront fee and allowance for credit loss, of crypto assets receivable, classified as non current.", "label": "Crypto Assets Receivable, After Unamortized Nonrefundable Upfront Fee And Allowance For Credit Loss, Non Current", "terseLabel": "Digital assets receivable, net" } } }, "auth_ref": [] }, "hypd_CryptoAssetsReceivableProvisionForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsReceivableProvisionForCreditLoss", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 8.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for credit loss on crypto assets receivable.", "label": "Crypto Assets Receivable, Provision For Credit Loss", "negatedLabel": "Provision for credit loss", "terseLabel": "Provision for credit losses", "verboseLabel": "Allowance for credit losses" } } }, "auth_ref": [] }, "hypd_CryptoAssetsReceivableRealizedCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsReceivableRealizedCreditLosses", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of realized credit losses on digital assets receivable during the reporting period.", "label": "Crypto Assets Receivable, Realized Credit Losses", "terseLabel": "Realized credit losses" } } }, "auth_ref": [] }, "hypd_CryptoAssetsReceivableUnamortizedNonrefundableUpfrontFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsReceivableUnamortizedNonrefundableUpfrontFee", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of unamortized nonrefundable upfront fee related to digital assets receivable during the reporting period.", "label": "Crypto Assets Receivable, Unamortized Nonrefundable Upfront Fee", "terseLabel": "Unamortized non-refundable upfront fee on digital asset receivable" } } }, "auth_ref": [] }, "hypd_CryptoAssetsReceivablesAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsReceivablesAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on crypto assets receivable.", "label": "Crypto Assets Receivables, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss" } } }, "auth_ref": [] }, "hypd_CryptoAssetsRevenueReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsRevenueReceivable", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of crypto asset revenue receivable.", "label": "Crypto Assets, Revenue Receivable", "terseLabel": "Revenue receivable" } } }, "auth_ref": [] }, "hypd_CryptoAssetsUsdh": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsUsdh", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The crypto assets of USDH.", "label": "Crypto Assets, USDH", "terseLabel": "USDH holdings" } } }, "auth_ref": [] }, "hypd_CryptoAssetsValueOfUnitsRedeemed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "CryptoAssetsValueOfUnitsRedeemed", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of crypto asset units redeemed during the period.", "label": "Crypto Assets, Value Of Units Redeemed", "terseLabel": "Impaired to value" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r6", "r30", "r31", "r66", "r67", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r660", "r661", "r662", "r663", "r664", "r695", "r821", "r822", "r824", "r827", "r856", "r857", "r858", "r928", "r930", "r940" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r255", "r458", "r459", "r661", "r662", "r695" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r33", "r256" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r6", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r660", "r661", "r662", "r663", "r664", "r695", "r821", "r822", "r824", "r827", "r856", "r857", "r858", "r928", "r930", "r940" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "terseLabel": "Number of monthly payments", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r6", "r27" ] }, "hypd_DebtInstrumentPeriodicPaymentNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DebtInstrumentPeriodicPaymentNumberOfInstallments", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of periodic installments in which debt is to be repaid.", "label": "Debt Instrument, Periodic Payment, Number of Installments", "terseLabel": "Number of installments" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "negatedTotalLabel": "Debt Discount, Total", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r866", "r927", "r928", "r930" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscountCurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount, Current", "negatedLabel": "Debt Discount", "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer." } } }, "auth_ref": [ "r927", "r928", "r930" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount, Noncurrent", "negatedLabel": "Debt Discount Non-Current", "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r927", "r928", "r930" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "verboseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "hypd_DepositOfDigitalAssetsIntoDigitalInvestmentAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DepositOfDigitalAssetsIntoDigitalInvestmentAccount", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital assets deposited by the entity into the digital investment account.", "label": "Deposit of Digital Assets Into Digital Investment Account", "terseLabel": "Deposits of USDH into Hyperion Rysk Vault" } } }, "auth_ref": [] }, "hypd_DepositOfDigitalAssetsIntoLiquidStakingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DepositOfDigitalAssetsIntoLiquidStakingActivities", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital assets deposited by the entity into liquid staking activities.", "label": "Deposit of Digital Assets Into Liquid Staking Activities", "terseLabel": "Deposits of digital assets into liquid staking activities" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r106", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r540", "r542", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r579", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r604", "r607", "r609", "r610", "r633", "r634", "r636", "r685", "r686", "r701", "r703", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r906", "r907", "r908", "r909", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r106", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r540", "r542", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r579", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r604", "r607", "r609", "r610", "r633", "r634", "r636", "r685", "r686", "r701", "r703", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r906", "r907", "r908", "r909", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Current", "negatedLabel": "Outstanding derivative liability", "terseLabel": "Derivative liability", "verboseLabel": "Outstanding derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r97" ] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of contracts reference", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r541", "r604", "r605", "r608", "r703", "r903", "r904" ] }, "us-gaap_DerivativePriceRiskOptionStrikePrice": { "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativePriceRiskOptionStrikePrice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative, Price Risk Option Strike Price", "terseLabel": "Strike prices ranging", "documentation": "The strike price on the price risk option contract such as a put option or a call option." } } }, "auth_ref": [ "r604", "r606" ] }, "hypd_DigitalAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalAssetsDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssets" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for digital assets.", "label": "Digital Assets Disclosure [Text Block]", "terseLabel": "Digital Assets" } } }, "auth_ref": [] }, "hypd_DigitalAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalAssetsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to digital assets.", "label": "Digital Assets [Member]", "terseLabel": "Digital Assets" } } }, "auth_ref": [] }, "hypd_DigitalAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policies for digital assets.", "label": "Digital Assets, Policy [Policy Text Block]", "terseLabel": "Digital Assets" } } }, "auth_ref": [] }, "hypd_DigitalAssetsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalAssetsReceivableMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to digital assets receivable.", "label": "Digital Assets Receivable [Member]", "terseLabel": "Digital Assets Receivable" } } }, "auth_ref": [] }, "hypd_DigitalAssetsReceivableProvisionForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalAssetsReceivableProvisionForCreditLoss", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for credit loss on digital assets receivable.", "label": "Digital Assets Receivable, Provision For Credit Loss", "terseLabel": "Provision for credit losses" } } }, "auth_ref": [] }, "hypd_DigitalIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalIntangibleAssetsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Digital intangible assets.", "label": "Digital Intangible Assets [Member]", "verboseLabel": "Intangible Assets" } } }, "auth_ref": [] }, "hypd_DigitalIntangibleAssetsNumberOfUnitsOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalIntangibleAssetsNumberOfUnitsOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the outstanding number of units of digital intangible assets.", "label": "Digital Intangible Assets, Number of Units Outstanding", "terseLabel": "Outstanding number of units of digital intangible assets" } } }, "auth_ref": [] }, "hypd_DigitalIntangibleAssetsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalIntangibleAssetsReceivable", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital intangible assets receivable.", "label": "Digital Intangible Assets, Receivable", "terseLabel": "Total" } } }, "auth_ref": [] }, "hypd_DigitalIntangibleAssetsReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalIntangibleAssetsReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital intangible assets receivable after allowance for credit loss.", "label": "Digital Intangible Assets, Receivable, After Allowance For Credit Loss", "terseLabel": "Digital intangible assets receivable, net" } } }, "auth_ref": [] }, "hypd_DigitalIntangibleAssetsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "DigitalIntangibleAssetsReceivableMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsReceivableDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to digital intangible assets receivable.", "label": "Digital Intangible Assets Receivable [Member]", "terseLabel": "Digital Intangible Assets Receivable" } } }, "auth_ref": [] }, "us-gaap_DilutiveSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DilutiveSecurities", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "terseLabel": "Dilutive securities outstanding", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": [ "r15" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of restricted stock units (\"RSUs\") activity", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r871" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Dividends Payable, Current", "terseLabel": "Accrued dividend", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r715" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r747" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r758" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Per Share of Common Stock", "verboseLabel": "Net Loss per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net Loss per Share - Basic (in dollars per share)", "verboseLabel": "Basic Net Income (Loss) Per Common Share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r81", "r104", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r139", "r142", "r150", "r153", "r154", "r158", "r274", "r350", "r378", "r383", "r428", "r429", "r477", "r494", "r643" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net Loss per Share - Diluted (in dollars per share)", "verboseLabel": "Diluted Net Income (Loss) Per Common Share (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r81", "r104", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r142", "r150", "r153", "r154", "r158", "r274", "r350", "r378", "r383", "r428", "r429", "r477", "r494", "r643" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStock" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Share of Common Stock", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r138", "r155", "r156", "r157" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r359", "r673" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "US Federal statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r111", "r116", "r359", "r370", "r673" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation expense", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stockholders' Equity (Deficit)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r898" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period of recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r348" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r899" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r713" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r713" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r713" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r797" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r713" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r713" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r713" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r713" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r752" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r793" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r793" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r793" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r79", "r80", "r81", "r101", "r102", "r103", "r122", "r123", "r124", "r126", "r133", "r135", "r137", "r160", "r202", "r203", "r228", "r273", "r304", "r350", "r368", "r369", "r375", "r376", "r377", "r379", "r382", "r383", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r451", "r452", "r453", "r454", "r455", "r456", "r460", "r461", "r464", "r493", "r510", "r511", "r512", "r527", "r591" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r762" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r720", "r730", "r740", "r772" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r717", "r727", "r737", "r769" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r263", "r443", "r444", "r446", "r629", "r661", "r662" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r768" ] }, "hypd_ExercisePrice197.5680Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice197.5680Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $197.5680.", "label": "Exercise Price $197.5680 [Member]", "terseLabel": "$197.5680" } } }, "auth_ref": [] }, "hypd_ExercisePrice217.9200Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice217.9200Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $217.9200.", "label": "Exercise Price $217.9200 [Member]", "terseLabel": "$217.9200" } } }, "auth_ref": [] }, "hypd_ExercisePrice3.2500Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice3.2500Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $3.2500.", "label": "Exercise Price $3.2500 [Member]", "terseLabel": "$3.2500" } } }, "auth_ref": [] }, "hypd_ExercisePrice380.8000Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice380.8000Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $380.8000.", "label": "Exercise Price $380.8000 [Member]", "terseLabel": "$380.8000" } } }, "auth_ref": [] }, "hypd_ExercisePrice4.0000Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice4.0000Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $4.0000.", "label": "Exercise Price $4.0000 [Member]", "terseLabel": "$4.0000" } } }, "auth_ref": [] }, "hypd_ExercisePrice5.2720Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice5.2720Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $5.2720.", "label": "Exercise Price $5.2720 [Member]", "terseLabel": "$5.2720" } } }, "auth_ref": [] }, "hypd_ExercisePrice8.6080Member": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ExercisePrice8.6080Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exercise price $8.6080.", "label": "Exercise Price $8.6080 [Member]", "terseLabel": "$8.6080" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Debt, Amount", "terseLabel": "Modification date carrying value of extinguished Avenue Loan", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "hypd_FairValueAdjustmentOfSharesIssuedForDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "FairValueAdjustmentOfSharesIssuedForDividend", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of shares issued for dividend.", "label": "Fair Value Adjustment of Shares Issued For Dividend", "terseLabel": "Change in fair value of shares issued for accrued dividend" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of digital assets subject to fair value measurements on a recurring basis and the level of inputs used for such measurements", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r911", "r912" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r263", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r430", "r432", "r433", "r434", "r435", "r438", "r439", "r441", "r443", "r469", "r470", "r471", "r629", "r661", "r662", "r667", "r668", "r669", "r670", "r671", "r688", "r690", "r694" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r263", "r443", "r444", "r445", "r446", "r447", "r448", "r629", "r661", "r662", "r925" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r431", "r432", "r433", "r435", "r688", "r914", "r924" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r263", "r309", "r314", "r315", "r432", "r439", "r443", "r469", "r629", "r667", "r668", "r669", "r670", "r671", "r688", "r694" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r263", "r309", "r314", "r315", "r317", "r432", "r433", "r439", "r443", "r470", "r629", "r661", "r662", "r667", "r668", "r669", "r670", "r671", "r688", "r694" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r263", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r432", "r433", "r434", "r435", "r439", "r443", "r471", "r629", "r661", "r662", "r667", "r668", "r669", "r670", "r671", "r688", "r690", "r694" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r431", "r432", "r433", "r435", "r688", "r914", "r924" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r263", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r430", "r432", "r433", "r434", "r435", "r438", "r439", "r441", "r443", "r469", "r470", "r471", "r629", "r661", "r662", "r667", "r668", "r669", "r670", "r671", "r688", "r690", "r694" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r688", "r911", "r912", "r913", "r914", "r915", "r924" ] }, "hypd_FirstInsuranceFundingLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "FirstInsuranceFundingLoanMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to FIRST Insurance Funding Loan.", "label": "First Insurance Funding Loan [Member]", "terseLabel": "FIRST Insurance Funding Loan" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r724", "r734", "r744", "r776" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r724", "r734", "r744", "r776" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r724", "r734", "r744", "r776" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r724", "r734", "r744", "r776" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r724", "r734", "r744", "r776" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r757" ] }, "hypd_FutureExpectedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "FutureExpectedPayments", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of future expected payments payable under the contract.", "label": "Future Expected Payments", "terseLabel": "Payments payable under the contract" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 5.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Net gains (losses) on derivative instruments", "negatedTerseLabel": "Net gains on derivative instruments", "terseLabel": "Net gains (losses) on derivative instruments", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r905" ] }, "hypd_GainLossOnExtinguishmentOfLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "GainLossOnExtinguishmentOfLiability", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of liability which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Liability", "negatedTerseLabel": "Gain on extinguishment of liabilities", "terseLabel": "Gain on extinguishment of liabilities" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Digital Assets" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross Profit", "verboseLabel": "Gross Income (Loss)", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r45", "r46", "r73", "r111", "r114", "r115", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r447", "r646", "r651", "r834", "r836", "r837", "r838", "r839", "r863" ] }, "hypd_HihypeLiquidStakingTokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HihypeLiquidStakingTokenMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HiHYPE liquid staking token.", "label": "Hihype Liquid Staking Token [Member]", "terseLabel": "HiHYPE" } } }, "auth_ref": [] }, "hypd_HplDigitalAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HplDigitalAssetsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HPL digital assets.", "label": "HPL Digital Assets [Member]", "terseLabel": "HPL Digital Assets" } } }, "auth_ref": [] }, "hypd_HplLiquidStakingTokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HplLiquidStakingTokenMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HPL liquid staking token.", "label": "HPL Liquid Staking Token [Member]", "terseLabel": "sHPL" } } }, "auth_ref": [] }, "hypd_HypeAssetUseServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HypeAssetUseServiceAgreementMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Hype Asset Use Service Agreement.", "label": "Hype Asset Use Service Agreement [Member]", "terseLabel": "Hype Asset Use Service Agreement" } } }, "auth_ref": [] }, "hypd_HypeDigitalAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HypeDigitalAssetsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hype digital assets.", "label": "Hype Digital Assets [Member]", "terseLabel": "HYPE Digital Assets", "verboseLabel": "HYPE digital assets" } } }, "auth_ref": [] }, "hypd_HypeLiquidStakedTokensMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HypeLiquidStakedTokensMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HYPE LSTs.", "label": "Hype Liquid Staked Tokens [Member]", "terseLabel": "HYPE LSTs" } } }, "auth_ref": [] }, "hypd_HyperionAndFelixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HyperionAndFelixMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hyperion and Felix.", "label": "Hyperion and Felix [Member]", "terseLabel": "Hyperion and Felix" } } }, "auth_ref": [] }, "hypd_HyperionRyskVaultSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HyperionRyskVaultSharesMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Hyperion Rysk vault shares bearing a technical name \"WHYPE-USDH-USDH-P-H-HL.", "label": "Hyperion Rysk Vault Shares [Member]", "terseLabel": "Hyperion Rysk Vault", "verboseLabel": "WHYPE-USDH-USDH-P-H-HL" } } }, "auth_ref": [] }, "hypd_HyperlendTokensMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "HyperlendTokensMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to HyperLend tokens.", "label": "HyperLend Tokens [Member]", "terseLabel": "HyperLend" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment loss - digital intangible assets", "verboseLabel": "Impairment loss - digital assets", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r215", "r819", "r842", "r843" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r229", "r232", "r233", "r390", "r396", "r413", "r414", "r436", "r437", "r440", "r448", "r449", "r450", "r507", "r509", "r576", "r628", "r629", "r674", "r675", "r686", "r687", "r689", "r694", "r901", "r902", "r945" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r232", "r233", "r390", "r396", "r413", "r414", "r436", "r437", "r440", "r448", "r449", "r450", "r507", "r509", "r576", "r628", "r629", "r674", "r675", "r686", "r687", "r689", "r694", "r901", "r902", "r945" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureIncomeTax" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r111", "r116", "r356", "r359", "r360", "r361", "r362", "r363", "r366", "r371", "r372", "r373", "r374", "r484", "r516", "r526", "r673" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r100", "r357", "r358", "r363", "r364", "r365", "r367", "r520" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r2" ] }, "hypd_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables.", "label": "Increase (Decrease) in License Fee and Expense Reimbursements Receivables", "negatedLabel": "License fee and expense reimbursements receivables" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r799", "r818" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "hypd_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of assumed vesting of restricted stock units.", "label": "Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units", "terseLabel": "Assumed vesting of restricted stock units" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Assumed exercise of warrants, treasury stock method", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r143", "r144", "r145", "r154", "r320" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r214", "r216", "r217", "r630", "r678", "r679", "r680", "r681", "r682", "r683" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Digital Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214", "r217", "r218", "r630", "r678", "r679", "r680", "r681", "r682", "r683" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Digital intangible assets", "verboseLabel": "Digital intangible assets, Carrying value", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r204", "r217", "r630" ] }, "hypd_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillGross", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before impairment of assets, excluding financial assets and goodwill, lacking physical substance with a indefinite life.", "label": "Indefinite Lived Intangible Assets (Excluding Goodwill), Gross", "terseLabel": "Digital intangible assets, Cost" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r214", "r216", "r217", "r630", "r678", "r679", "r680", "r681", "r682", "r683" ] }, "hypd_IndefiniteLivedIntangibleAssetsNumberOfUnits": { "xbrltype": "decimalItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "IndefiniteLivedIntangibleAssetsNumberOfUnits", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of indefinite-lived intangible asset units held.", "label": "Indefinite Lived Intangible Assets, Number Of Units", "terseLabel": "Digital intangible assets, Units" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r724", "r734", "r744", "r768", "r776", "r780", "r788" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r786" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r716", "r792" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r716", "r792" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r716", "r792" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r50", "r268", "r272", "r663", "r664", "r977" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expenses", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r50", "r269", "r663", "r664" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Expense Nonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r175", "r638", "r641", "r815" ] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestIncomeOperating", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Interest Income, Operating", "terseLabel": "Interest income", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r174", "r482", "r483", "r573", "r613", "r614", "r651", "r709", "r710", "r813", "r980" ] }, "us-gaap_InterestPaidCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestPaidCapitalized", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Interest", "documentation": "Amount of cash paid for interest capitalized, classified as investing activity." } } }, "auth_ref": [ "r642", "r820" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r159", "r174", "r193", "r651", "r814" ] }, "hypd_InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "InvestorWarrantsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for investor warrants.", "label": "Investor Warrants [Member]", "terseLabel": "Investor warrants" } } }, "auth_ref": [] }, "hypd_IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of issuance of common stock related to vested restricted stock units.", "label": "Issuance of Common Stock Related to Vested Restricted Stock Units", "terseLabel": "Issuance of common stock upon vesting of restricted stock units" } } }, "auth_ref": [] }, "hypd_KhypeLiquidStakingTokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "KhypeLiquidStakingTokenMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to kHYPE liquid staking token.", "label": "Khype Liquid Staking Token [Member]", "terseLabel": "kHYPE" } } }, "auth_ref": [] }, "hypd_KinetiqResearchPteAndPierTwoPtyLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "KinetiqResearchPteAndPierTwoPtyLtdMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Kinetiq Research Pte (\"Kinetiq\") and Pier Two Pty Ltd (\"Pier Two\").", "label": "Kinetiq Research Pte And Pier Two Pty Ltd [Member]", "terseLabel": "Kinetiq and Pier Two" } } }, "auth_ref": [] }, "hypd_KmhypeLiquidStakingTokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "KmhypeLiquidStakingTokenMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to kmHYPE liquid staking token.", "label": "Kmhype Liquid Staking Token [Member]", "terseLabel": "kmHYPE" } } }, "auth_ref": [] }, "hypd_KntqLiquidStakingTokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "KntqLiquidStakingTokenMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to KNTQ liquid staking token.", "label": "KNTQ Liquid Staking Token [Member]", "terseLabel": "sKNTQ" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r6", "r30", "r31", "r32", "r34", "r35", "r36", "r37", "r111", "r114", "r115", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r386", "r387", "r388", "r447", "r550", "r645", "r665", "r711", "r863", "r931", "r932" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r44", "r69", "r491", "r696", "r699", "r700", "r821", "r826", "r840", "r926" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r32", "r88", "r111", "r114", "r115", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r386", "r387", "r388", "r447", "r696", "r863", "r931", "r932" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "auth_ref": [] }, "hypd_LiabilityForDigitalAssetsReceivedFromLenderPriorToLoanOrigination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LiabilityForDigitalAssetsReceivedFromLenderPriorToLoanOrigination", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital assets deposited by the entity into liquid staking activities.", "label": "Liability for digital assets received from lender, prior to loan origination", "terseLabel": "Liability for digital assets received from lender, prior to loan origination" } } }, "auth_ref": [] }, "hypd_LiquidStakingTokenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LiquidStakingTokenMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to liquid staking token.", "label": "Liquid Staking Token [Member]", "terseLabel": "HiHYPE" } } }, "auth_ref": [] }, "hypd_LiquidityPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LiquidityPlanAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Management's Liquidity Plans" } } }, "auth_ref": [] }, "hypd_LiquidityPlanDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LiquidityPlanDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlans" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for management's liquidity plan.", "label": "Liquidity Plan, Disclosure [Text Block]", "terseLabel": "Management's Liquidity Plans" } } }, "auth_ref": [] }, "hypd_LiquidityPlanLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LiquidityPlanLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liquidity Plan [Line Items]", "terseLabel": "Management's Liquidity Plans" } } }, "auth_ref": [] }, "hypd_LiquidityPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LiquidityPlanTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about liquidity plan.", "label": "Liquidity Plan [Table]" } } }, "auth_ref": [] }, "hypd_LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "LoanAndSecurityAgreementWithAvenueVentureOpportunitiesFundL.p.AndAvenueVentureOpportunitiesFundL.p.IiMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Loan and Security Agreement with Avenue, the Lender.", "label": "Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P., and Avenue Venture Opportunities Fund, L.P. II [Member]", "terseLabel": "Avenue Ventures Loan" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r6", "r67", "r112", "r121", "r262", "r271", "r481", "r661", "r662", "r695", "r942" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r112", "r121", "r266", "r481" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r112", "r121", "r266", "r481" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Noncurrent", "terseLabel": "Net Non-Current", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r6" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r166", "r238", "r239", "r240", "r243", "r353", "r659", "r861", "r862" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r166", "r238", "r239", "r240", "r243", "r353", "r659", "r861", "r862" ] }, "hypd_MarketRevenuesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "MarketRevenuesPercentage", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the percentage Market revenues based on trading volume tiers, plus of staking rewards.", "label": "Market Revenues Percentage", "terseLabel": "Market revenues percentage" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r166", "r239", "r240", "r241", "r242", "r318", "r343", "r344", "r345", "r353", "r435", "r475", "r506", "r508", "r515", "r541", "r542", "r596", "r598", "r601", "r602", "r611", "r621", "r622", "r623", "r624", "r626", "r627", "r656", "r666", "r672", "r674", "r676", "r677", "r690", "r691", "r692", "r693", "r697", "r865", "r933", "r934", "r935", "r936", "r937", "r938" ] }, "hypd_May2026PublicEquityIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "May2026PublicEquityIssuanceMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to May 2026 public equity issuance.", "label": "May 2026 Public Equity Issuance [Member]", "terseLabel": "May 2026 public equity issuance" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r760" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r760" ] }, "hypd_MerentiManagementGmbhMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "MerentiManagementGmbhMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Merenti Management GmbH.", "label": "Merenti Management Gmbh [Member]", "terseLabel": "Merenti Management GmbH" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r166", "r239", "r240", "r241", "r242", "r318", "r343", "r344", "r345", "r353", "r435", "r475", "r506", "r508", "r515", "r541", "r542", "r596", "r598", "r601", "r602", "r611", "r621", "r622", "r623", "r624", "r626", "r627", "r656", "r666", "r672", "r674", "r676", "r677", "r690", "r691", "r692", "r697", "r865", "r933", "r934", "r935", "r936", "r937", "r938" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r779" ] }, "hypd_ModificationOfDebtFairValueAtModificationDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ModificationOfDebtFairValueAtModificationDate", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The fair value of debt modified at the modification date in noncash investing or financing activities.", "label": "Modification of Debt, Fair Value at Modification Date", "terseLabel": "Modification date fair value of modified Avenue Loan" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r787" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r761" ] }, "hypd_NativeMarketsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NativeMarketsIncMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Native Markets, Inc.", "label": "Native Markets Inc [Member]", "terseLabel": "Native Markets Inc" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash and Cash Equivalents Provided By Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r107" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash and Cash Equivalents Used In Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r107" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows From Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Cash used in operating activities", "totalLabel": "Net Cash and Cash Equivalents Used In Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r53", "r54", "r55" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_UndistributedEarnings", "weight": 1.0, "order": 1.0 }, "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss)", "verboseLabel": "Net income (loss)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r47", "r55", "r70", "r81", "r86", "r98", "r99", "r103", "r111", "r114", "r115", "r118", "r125", "r129", "r130", "r131", "r132", "r133", "r136", "r137", "r147", "r201", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r274", "r278", "r281", "r285", "r350", "r378", "r383", "r429", "r447", "r492", "r571", "r589", "r590", "r638", "r640", "r641", "r710", "r863" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Income (Loss) Available to Common Stockholders", "verboseLabel": "Net income (loss) available to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r81", "r105", "r129", "r130", "r131", "r132", "r139", "r140", "r149", "r154", "r278", "r281", "r285", "r383" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "auth_ref": [] }, "hypd_NewAccountingPronouncementsIssuedPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NewAccountingPronouncementsIssuedPolicyPolicyTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements issued that may impact the entity's financial reporting.", "label": "New Accounting Pronouncements Issued, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "auth_ref": [] }, "hypd_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NonCashLeaseExpense", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for lease expenses.", "label": "Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "auth_ref": [] }, "hypd_NonCashPortionOfOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NonCashPortionOfOtherIncome", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of portion of other income recognized that result in no cash inflow (outflow).", "label": "Non-Cash Portion of Other Income", "negatedLabel": "Non-cash portion of other income" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r760" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r724", "r734", "r744", "r768", "r776" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r751" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r750" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r768" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r787" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r787" ] }, "hypd_NonRule10b51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NonRule10b51ArrangementModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Non Rule 10b5-1 Arrangement Modified [Flag]", "label": "Non Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Non Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "hypd_NoncashInterestIncomeFromDigitalAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NoncashInterestIncomeFromDigitalAssetsReceivables", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of interest income from digital assets receivable, that result in no cash inflow (outflow).", "label": "Noncash Interest Income From Digital Assets Receivables", "negatedLabel": "Non-cash interest income from digital assets receivable" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities" } } }, "auth_ref": [] }, "hypd_NoncashRevenuesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NoncashRevenuesNet", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of net revenue recognized that result in no cash inflow (outflow).", "label": "Noncash Revenues, Net", "negatedLabel": "Non-cash revenue, net" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "totalLabel": "Total Other Income (Expense), Net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesPayable", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payables", "totalLabel": "Notes Payable, Total", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r6", "r67", "r942", "r943" ] }, "us-gaap_NotesPayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesPayableAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotesPayableCurrentAbstract", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Current [Abstract]", "terseLabel": "Current portion" } } }, "auth_ref": [] }, "hypd_NotesPayableCurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NotesPayableCurrentGross", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": "hypd_NotesPayableGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs of notes payable classified as current.", "label": "Notes Payable, Current, Gross", "terseLabel": "Notes Payable" } } }, "auth_ref": [] }, "hypd_NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable, net of debt discount due within one year or the operating cycle if longer.", "label": "Notes Payable Current, Net Of Debt Discount Current, Current Portion", "terseLabel": "Net Current" } } }, "auth_ref": [] }, "hypd_NotesPayableDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NotesPayableDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayable" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of notes payable.", "label": "Notes Payable Disclosure [Text Block]", "terseLabel": "Notes Payable" } } }, "auth_ref": [] }, "hypd_NotesPayableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NotesPayableGross", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs of notes payable.", "label": "Notes Payable, Gross", "totalLabel": "Notes payable total" } } }, "auth_ref": [] }, "hypd_NotesPayableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NotesPayableLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Notes Payable [Line Items]", "terseLabel": "Notes Payable" } } }, "auth_ref": [] }, "hypd_NotesPayableNonCurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NotesPayableNonCurrentGross", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails": { "parentTag": "hypd_NotesPayableGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs of notes payable classified as non-current.", "label": "Notes Payable, Non-Current, Gross", "terseLabel": "Notes Payable Non-Current" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r652", "r835" ] }, "hypd_NumberOfPartnershipAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NumberOfPartnershipAgreements", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of partnership agreements.", "label": "Number of Partnership Agreements", "terseLabel": "Number of partnership agreements" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r647", "r655", "r835" ] }, "hypd_NumberOfVotesPerCommonShare": { "xbrltype": "integerItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "NumberOfVotesPerCommonShare", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of votes per share of common stock.", "label": "Number Of Votes Per Common Share", "terseLabel": "Number of votes" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Net Operating (Income) Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r641" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Less:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income (Loss) From Operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r73", "r638", "r641", "r646", "r834", "r836", "r837", "r838", "r839" ] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLossAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss) [Abstract]", "terseLabel": "Operating (Income) Expenses:" } } }, "auth_ref": [] }, "hypd_OperatingIncomeLossExcludingReconcilingItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "OperatingIncomeLossExcludingReconcilingItems", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues reconciling items.", "label": "Operating Income Loss Excluding Reconciling Items", "terseLabel": "Segment (income) loss" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities, non-current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r462" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r194", "r651", "r652" ] }, "hypd_OphthalmicTechnologySegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "OphthalmicTechnologySegmentMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to ophthalmic technology.", "label": "Ophthalmic Technology Segment [Member]", "terseLabel": "Ophthalmic Technology" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Business Organization, Nature of Operations and Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Business Organization, Nature of Operations and Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r62", "r82", "r83", "r84", "r517", "r518" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets", "verboseLabel": "All other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r64", "r90", "r486", "r652", "r699", "r700", "r711" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r95", "r696" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r90" ] }, "hypd_OtherDigitalAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "OtherDigitalAssetsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to other digital assets.", "label": "Other Digital Assets [Member]", "terseLabel": "Other digital assets" } } }, "auth_ref": [] }, "us-gaap_OtherLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Notes Payable, Noncurrent", "terseLabel": "Notes payable - non-current portion", "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r51", "r684" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r760" ] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Research and Development Expense", "terseLabel": "Other Expenses", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r900" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r722", "r732", "r742", "r774" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r725", "r735", "r745", "r777" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r725", "r735", "r745", "r777" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Paid-in-Kind Interest", "terseLabel": "Paid-in-kind interest expense", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r3" ] }, "hypd_PartnershipAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PartnershipAgreementMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to partnership agreement.", "label": "Partnership Agreement [Member]", "terseLabel": "Partnership agreement" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r749" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_PaymentForAcquisitionCryptoAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentForAcquisitionCryptoAsset", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment for Acquisition, Crypto Asset", "negatedTerseLabel": "Purchase of digital assets", "documentation": "Amount of cash outflow to acquire crypto asset. Excludes crypto asset held for platform user." } } }, "auth_ref": [ "r817" ] }, "hypd_PaymentsForStockIssuanceCostsWarrantsExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PaymentsForStockIssuanceCostsWarrantsExercises", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the stock issuance costs on exercise of warrants.", "label": "Payments For Stock Issuance Costs, Warrants Exercises", "terseLabel": "Issuance costs warrants exercises" } } }, "auth_ref": [] }, "hypd_PaymentsOfCostsOnInducedExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PaymentsOfCostsOnInducedExerciseOfWarrants", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash associated with costs incurred on induced exercise of warrants.", "label": "Payments of Costs on Induced Exercise of Warrants", "negatedLabel": "Payment of cash issuance costs for induced exercise of stock warrants" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfDebtRestructuringCosts", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Restructuring Costs", "negatedLabel": "Payment of issuance costs for debt modification", "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r7" ] }, "hypd_PaymentsOfStockIssuanceCostsAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PaymentsOfStockIssuanceCostsAtMarketOffering", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly in at the market offering with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs, At the Market Offering", "negatedLabel": "Payment of issuance costs for At the Market offering" } } }, "auth_ref": [] }, "hypd_PayrollTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PayrollTaxesReceivable", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Payroll Taxes Receivable.", "label": "Payroll Taxes Receivable", "verboseLabel": "Payroll tax receivable" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r759" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r759" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r751" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r768" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r761" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r750" ] }, "hypd_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement agent warrants" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r752" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r796" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r751" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r629", "r925" ] }, "hypd_PreferredStockAccruedDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PreferredStockAccruedDividends", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued dividends of preferred stock in noncash investing or financing transactions.", "label": "Preferred Stock, Accrued Dividends", "terseLabel": "Accrued dividend payable to preferred stockholders" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockConvertibleConversionRatio", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Preferred stock convertible ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": [ "r289" ] }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendRatePerDollarAmount", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "terseLabel": "Preferred stock dividend rate", "documentation": "The amount per share used to calculated dividend payments on preferred stock." } } }, "auth_ref": [ "r288" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Cumulative dividend rate", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r288", "r597", "r599", "r600", "r612" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_UndistributedEarnings", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Dividend to preferred stockholders", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockDividendsShares", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Dividends, Shares", "terseLabel": "Preferred stock dividends shares", "verboseLabel": "Preferred stock dividends paid", "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference, Value", "terseLabel": "Liquidation preference", "verboseLabel": "Preferred stock liquidation preference", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": [ "r111", "r113", "r292", "r303" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockMember", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r701", "r702", "r705", "r706", "r707", "r708", "r974", "r978" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAuthorizedCapitalDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r38", "r287" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAuthorizedCapitalDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r38", "r552" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r38", "r287" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r38", "r552", "r570", "r978", "r979" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value, 60,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock, 5,435,898 shares designated; 5,235,897 and 5,435,897 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively with a liquidation preference of $50,768,000 as of March 31, 2026", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r38", "r277", "r283", "r489", "r696" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Total prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r803" ] }, "hypd_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "hypd_PrepaidGeneralAndAdministrativeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PrepaidGeneralAndAdministrativeExpenses", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Prepaid general and administrative expenses.", "label": "Prepaid General and Administrative Expenses", "terseLabel": "Prepaid general and administrative expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance expenses", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r632", "r657", "r841" ] }, "hypd_PrepaidPatentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PrepaidPatentExpense", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of prepaid patent expense.", "label": "Prepaid Patent Expense", "terseLabel": "Prepaid patent expenses" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r800" ] }, "hypd_PrivatePoolParticipationAgreementAndRevenueSharingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PrivatePoolParticipationAgreementAndRevenueSharingAgreementMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private pool participation agreement and revenue sharing agreement.", "label": "Private Pool Participation Agreement and Revenue Sharing Agreement [Member]", "terseLabel": "Private Pool Participation Agreement and Revenue-Sharing Agreement" } } }, "auth_ref": [] }, "hypd_PrivatePoolParticipationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PrivatePoolParticipationAgreementMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Private Pool Participation Agreement.", "label": "Private Pool Participation Agreement [Member]", "terseLabel": "Private Pool Participation Agreement" } } }, "auth_ref": [] }, "hypd_ProceedsFromInducedExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ProceedsFromInducedExerciseOfWarrants", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received on induced exercise of warrants.", "label": "Proceeds From Induced Exercise of Warrants", "terseLabel": "Proceeds from induced exercise of stock warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "hypd_ProceedsFromIssuanceOfCommonStockAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ProceedsFromIssuanceOfCommonStockAtMarketOffering", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from issuance of common stock at market offering.", "label": "Proceeds from Issuance of Common Stock at Market Offering", "terseLabel": "Proceeds from sale of common stock in At the Market offering" } } }, "auth_ref": [] }, "hypd_ProceedsFromIssuanceOfPreferredStockAndWarrantsPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ProceedsFromIssuanceOfPreferredStockAndWarrantsPrivatePlacement", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with issuance of preferred stock and warrants under private placement.", "label": "Proceeds From Issuance Of Preferred Stock and Warrants, Private Placement", "terseLabel": "Proceeds from sale of preferred stock and warrants in private placement" } } }, "auth_ref": [] }, "hypd_ProceedsOfStockIssuedDuringPeriodGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ProceedsOfStockIssuedDuringPeriodGross", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount of issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds Of Stock Issued During Period Gross", "terseLabel": "Proceeds of stock issued during period gross" } } }, "auth_ref": [] }, "hypd_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "PurchaseOfInsurancePremiumFinancedByShortTermNotePayable", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of purchase of insurance premium financed by short term notes payable.", "label": "Purchase of Insurance Premium Financed by Short Term Note Payable", "terseLabel": "Prepaid insurance financed by note payable" } } }, "auth_ref": [] }, "us-gaap_PutOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PutOptionMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Put Option [Member]", "terseLabel": "Put Option", "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option." } } }, "auth_ref": [ "r603", "r604" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r749" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r749" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": [ "r166", "r239", "r240", "r241", "r242", "r308", "r318", "r343", "r344", "r345", "r349", "r353", "r435", "r472", "r473", "r475", "r506", "r508", "r515", "r541", "r542", "r596", "r598", "r601", "r602", "r611", "r621", "r622", "r623", "r624", "r626", "r627", "r656", "r666", "r672", "r674", "r676", "r677", "r690", "r691", "r692", "r693", "r697", "r703", "r859", "r865", "r914", "r934", "r935", "r936", "r937", "r938" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsOtcHypeOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "auth_ref": [ "r166", "r239", "r240", "r241", "r242", "r308", "r318", "r343", "r344", "r345", "r349", "r353", "r435", "r472", "r473", "r475", "r506", "r508", "r515", "r541", "r542", "r596", "r598", "r601", "r602", "r611", "r621", "r622", "r623", "r624", "r626", "r627", "r656", "r666", "r672", "r674", "r676", "r677", "r690", "r691", "r692", "r693", "r697", "r703", "r859", "r865", "r914", "r934", "r935", "r936", "r937", "r938" ] }, "hypd_ReceiptOfDigitalAssetsFromLiquidStakingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ReceiptOfDigitalAssetsFromLiquidStakingActivities", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital assets received by the entity from liquid staking activities.", "label": "Receipt of Digital Assets From Liquid Staking Activities", "terseLabel": "Receipt of digital assets from liquid staking activities" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r21", "r22" ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Schedule of segment assets", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r21", "r22" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of activity of Company's segments", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r20", "r22" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r717", "r727", "r737", "r769" ] }, "hypd_RedemptionOfDigitalAssetsFromDigitalInvestmentAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "RedemptionOfDigitalAssetsFromDigitalInvestmentAccount", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of digital assets redeemed by the entity from the digital investment account.", "label": "Redemption of Digital Assets From Digital Investment Account", "terseLabel": "Redemption of digital assets from Hyperion Rysk Vault" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable", "negatedLabel": "Repayments of notes payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r52" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesJointValidatorOperatorsAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r111", "r119", "r120", "r258", "r290", "r465", "r474", "r485", "r634", "r635", "r636", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r906", "r907", "r908", "r909" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r355", "r628", "r638", "r639", "r651", "r939" ] }, "us-gaap_ResearchAndDevelopmentExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseAbstract", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Abstract]", "terseLabel": "Research and Development:" } } }, "auth_ref": [] }, "hypd_ResearchAndDevelopmentExpenseDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ResearchAndDevelopmentExpenseDepreciationExpense", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of depreciation expense attributable to research and development.", "label": "Research and Development Expense, Depreciation Expense", "terseLabel": "Depreciation expense" } } }, "auth_ref": [] }, "hypd_ResearchAndDevelopmentExpenseDirectClinicalAndNonClinicalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ResearchAndDevelopmentExpenseDirectClinicalAndNonClinicalExpenses", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for direct clinical and non-clinical expenses attributable to research and development.", "label": "Research and Development Expense, Direct Clinical And Non Clinical Expenses", "terseLabel": "Direct clinical and non-clinical expenses" } } }, "auth_ref": [] }, "hypd_ResearchAndDevelopmentExpenseFacilitiesExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ResearchAndDevelopmentExpenseFacilitiesExpenses", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for facilities attributable to research and development.", "label": "Research and Development Expense, Facilities Expenses", "terseLabel": "Facilities expenses" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research And Development Expense [Member]", "verboseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "hypd_ResearchAndDevelopmentExpenseNonCashStockBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ResearchAndDevelopmentExpenseNonCashStockBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash stock based compensation expenses attributable to research and development.", "label": "Research and Development Expense, Non Cash Stock Based Compensation Expense", "terseLabel": "Non-cash stock based compensation expenses" } } }, "auth_ref": [] }, "hypd_ResearchAndDevelopmentExpenseSalariesAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ResearchAndDevelopmentExpenseSalariesAndBenefits", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for salaries and other employee benefits attributable to research and development.", "label": "Research and Development Expense, Salaries And Benefits", "terseLabel": "Salaries and benefits" } } }, "auth_ref": [] }, "hypd_ResearchAndDevelopmentExpenseSuppliesAndMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ResearchAndDevelopmentExpenseSuppliesAndMaterials", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense for supplies and materials attributable to research and development.", "label": "Research and Development Expense, Supplies And Materials", "terseLabel": "Supplies and materials" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r718", "r728", "r738", "r770" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r719", "r729", "r739", "r771" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r726", "r736", "r746", "r778" ] }, "hypd_RestrictedStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "RestrictedStockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "This represents restricted stock units issued during the period.", "label": "Restricted Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock from the delivery of vested restricted stock units (in shares)" } } }, "auth_ref": [] }, "hypd_RestrictedStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "RestrictedStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of restricted stock issued during the period.", "label": "Restricted Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock from the delivery of vested restricted stock units" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "verboseLabel": "Unvested RSU", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r41", "r60", "r490", "r513", "r514", "r525", "r553", "r696" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r79", "r80", "r81", "r122", "r123", "r124", "r126", "r133", "r135", "r137", "r202", "r203", "r228", "r273", "r350", "r368", "r369", "r375", "r376", "r377", "r379", "r382", "r383", "r416", "r418", "r419", "r421", "r427", "r460", "r461", "r510", "r512", "r527", "r978" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r71", "r72", "r159", "r172", "r173", "r187", "r193", "r196", "r198", "r199", "r305", "r306", "r307", "r476", "r638", "r641" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Customer benefits period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r77" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r77" ] }, "hypd_RevenueSharingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "RevenueSharingAgreementMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Revenue-Sharing Agreement.", "label": "Revenue Sharing Agreement [Member]", "terseLabel": "Revenue-Sharing Agreement" } } }, "auth_ref": [] }, "hypd_ReverseStockSplitSettlementOfFractionalShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ReverseStockSplitSettlementOfFractionalShares", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of reverse stock split settlement of fractional shares.", "label": "Reverse Stock Split Settlement of Fractional Shares", "negatedLabel": "Reverse stock split settlement of fractional shares" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r787" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r787" ] }, "hypd_Rule10b51ArrangementModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "Rule10b51ArrangementModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Rule 10b5-1 Arrangement Modified [Flag]", "label": "Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from At-the-Market Offering Program", "verboseLabel": "Net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accrued expenses and other current liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r155" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of securities are excluded from the calculation of weighted average diluted shares of common stock", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net income (loss) per common share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r833" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalIntangibleAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDigitalIntangibleAssetsReceivableAndCreditLossAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r214", "r217", "r218", "r630", "r678", "r679", "r680", "r681", "r682", "r683" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of digital intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r630", "r842" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "verboseLabel": "Schedule of avenue loan maturities", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r4" ] }, "hypd_ScheduleOfNotesPayableTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ScheduleOfNotesPayableTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableAvenueLoanMaturitiesDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableDetails", "http://www.eyenoviabio.com/role/DisclosureNotesPayableFirstInsuranceFundingLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a long term notes to be paid to the borrowers.", "label": "Schedule of Notes Payable [Table]" } } }, "auth_ref": [] }, "hypd_ScheduleOfNotesPayableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ScheduleOfNotesPayableTableTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of notes payable.", "label": "Schedule of Notes Payable [Table Text Block]", "terseLabel": "Schedule of notes payable and convertible notes payable" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r17", "r18", "r19" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "verboseLabel": "Schedule of the warrant activity and related information", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r869" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r712" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r714" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r159", "r168", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r199", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r218", "r234", "r235", "r380", "r381", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r648", "r651", "r652", "r658", "r698", "r944", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingAssetReconcilingItemLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReporting" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r74", "r159", "r167", "r168", "r169", "r170", "r171", "r183", "r185", "r186", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r199", "r647", "r649", "r650", "r651", "r653", "r654", "r655" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r48", "r637", "r638", "r639", "r641", "r816" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "verboseLabel": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [ "r674", "r675" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock", "verboseLabel": "Series A Convertible Preferred", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r801", "r802", "r867", "r868" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r335" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "RSUs non-vested March 31, 2026", "periodStartLabel": "RSUs non-vested January 1, 2026", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r332", "r333" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of RSUs", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r336" ] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested RSUs Undelivered numbers during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested R S Us Undelivered, Number", "verboseLabel": "Vested RSUs undelivered March 31, 2026" } } }, "auth_ref": [] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsDeliveredInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsDeliveredInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees delivered the restricted stock units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Delivered In Period, Weighted Average Exercise Price", "terseLabel": "Delivered" } } }, "auth_ref": [] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of restricted stock units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Grants In Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "auth_ref": [] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the restricted stock unit plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Non Vested, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "RSUs non-vested March 31, 2026", "periodStartLabel": "RSUs non-vested January 1, 2026" } } }, "auth_ref": [] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price [Roll forward]", "terseLabel": "Weighted Average Grant Date Price" } } }, "auth_ref": [] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees vested the restricted stock units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested In Period, Weighted Average Exercise Price", "terseLabel": "Vested" } } }, "auth_ref": [] }, "hypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees vested the restricted stock units undelivered.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Vested R S Us Undelivered, Weighted Average Exercise Price", "terseLabel": "Vested RSUs undelivered March 31, 2026" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346" ] }, "hypd_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsdeliveredinperiod": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsdeliveredinperiod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that was delivered during the reporting period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDeliveredInPeriod", "negatedLabel": "Delivered" } } }, "auth_ref": [] }, "hypd_SharesIssuedForAccruedDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "SharesIssuedForAccruedDividends", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of shares issued for dividends payable in noncash investing or financing transactions.", "label": "Shares Issued For Accrued Dividends", "terseLabel": "Common stock issued for accrued dividends payable" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Shares Issued price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermBankLoansAndNotesPayable", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term Bank Loans and Notes Payable", "verboseLabel": "Notes payable - current portion", "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": [ "r28", "r547", "r941" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r109", "r110" ] }, "hypd_SilhouetteGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "SilhouetteGMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Silhouette AG.", "label": "Silhouette A G [Member]", "terseLabel": "Silhouette AG" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSegmentAssetsDetails", "http://www.eyenoviabio.com/role/DisclosureSegmentReportingSignificantExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r85", "r159", "r168", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r199", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r218", "r230", "r234", "r235", "r380", "r381", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r648", "r651", "r652", "r658", "r698", "r944", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r78", "r92", "r93", "r94", "r111", "r115", "r142", "r146", "r150", "r154", "r161", "r162", "r201", "r244", "r247", "r248", "r249", "r253", "r254", "r276", "r277", "r279", "r280", "r282", "r284", "r287", "r288", "r292", "r295", "r301", "r447", "r521", "r522", "r523", "r524", "r527", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r552", "r572", "r591", "r615", "r616", "r617", "r618", "r619", "r798", "r823", "r825", "r832" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r39", "r42", "r43", "r79", "r80", "r81", "r101", "r102", "r103", "r122", "r123", "r124", "r126", "r133", "r135", "r137", "r160", "r202", "r203", "r228", "r273", "r304", "r350", "r368", "r369", "r375", "r376", "r377", "r379", "r382", "r383", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r451", "r452", "r453", "r454", "r455", "r456", "r460", "r461", "r464", "r493", "r510", "r511", "r512", "r527", "r591" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r122", "r123", "r124", "r160", "r276", "r277", "r279", "r282", "r461", "r476", "r519", "r528", "r539", "r543", "r544", "r545", "r546", "r548", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r574", "r575", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r591", "r640", "r641", "r704", "r976" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Statements of Changes in Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r122", "r123", "r124", "r160", "r200", "r276", "r277", "r279", "r282", "r461", "r476", "r519", "r528", "r539", "r543", "r544", "r545", "r546", "r548", "r549", "r552", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r574", "r575", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r591", "r640", "r641", "r704", "r976" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r721", "r731", "r741", "r773" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897" ] }, "hypd_StockIssuedAtMarketOfferingDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockIssuedAtMarketOfferingDuringPeriodSharesNewIssues", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "This represents shares issued at market offering.", "label": "Stock Issued at Market Offering During Period Shares New Issues", "terseLabel": "Issuance of common stock in At the Market offering (in shares)" } } }, "auth_ref": [] }, "hypd_StockIssuedAtMarketOfferingDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockIssuedAtMarketOfferingDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "The amount of common stock issued in at the market offering.", "label": "Stock Issued at Market Offering During Period Value New Issues", "terseLabel": "Issuance of common stock in At the Market offering" } } }, "auth_ref": [] }, "hypd_StockIssuedDuringPeriodSharesConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredStock", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of preferred stock.", "label": "Stock Issued During Period, Shares, Conversion of Preferred Stock", "terseLabel": "Issuance of common stock from conversion of preferred stock (in shares)" } } }, "auth_ref": [] }, "hypd_StockIssuedDuringPeriodSharesInducedExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockIssuedDuringPeriodSharesInducedExerciseOfWarrants", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued upon induced exercise of warrants.", "label": "Stock Issued During Period, Shares, Induced Exercise of Warrants", "terseLabel": "Induced exercise of stock warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Compensation received for services (in shares)", "verboseLabel": "Issuance of common stock to vendors in consideration for service provided (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of common shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r38", "r39", "r60", "r521", "r591", "r616" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "negatedLabel": "Reverse stock split settlement of fractional shares (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r5" ] }, "hypd_StockIssuedDuringPeriodValueConversionOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockIssuedDuringPeriodValueConversionOfPreferredStock", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of preferred stock.", "label": "Stock Issued During Period, Value, Conversion of Preferred Stock", "terseLabel": "Issuance of common stock from conversion of preferred stock" } } }, "auth_ref": [] }, "hypd_StockIssuedDuringPeriodValueInducedExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockIssuedDuringPeriodValueInducedExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period upon induced exercise of warrants.", "label": "Stock Issued During Period, Value, Induced Exercise of Warrants", "terseLabel": "Induced exercise of stock warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Value of received securities", "verboseLabel": "Issuance of common stock to vendors in consideration for service provided", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Dividend", "terseLabel": "Issuance of common stock for payment in kind of preferred stock dividend", "documentation": "Value of stock issued to shareholders as a dividend during the period." } } }, "auth_ref": [ "r5", "r39", "r42", "r43", "r60" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Retired", "negatedLabel": "Retirement of treasury shares (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r5", "r38", "r39", "r60" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Retired, Cost Method, Amount", "negatedLabel": "Retirement of treasury shares", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r5", "r38", "r39", "r60" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Stockholders' Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r39", "r42", "r43", "r56", "r554", "r570", "r592", "r593", "r696", "r711", "r821", "r825", "r826", "r840", "r926", "r978" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity" } } }, "auth_ref": [] }, "hypd_StockholdersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockholdersEquityLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References", "label": "Stockholders' Equity [Line Items]", "terseLabel": "Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r59", "r286", "r288", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r304", "r415", "r426", "r594", "r595", "r620" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r61" ] }, "hypd_StockholdersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "StockholdersEquityTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitCommonStockIssuancesDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to Stockholders Equity.", "label": "Stockholders Equity [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r457", "r467" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "terseLabel": "Subsequent Events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r457", "r467" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTable", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r457", "r467" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r457", "r467" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r457", "r467" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r466", "r468" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAtMarketProgramDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r767" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "terseLabel": "Accrued foreign tax", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r31" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r759" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r766" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r786" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r788" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "hypd_TransferOfCryptoAssetsToDigitalAssetReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "TransferOfCryptoAssetsToDigitalAssetReceivable", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of transfer of crypto assets to digital asset receivable.", "label": "Transfer Of Crypto Assets To Digital Asset Receivable", "terseLabel": "Transfer of digital intangible assets into digital intangible assets receivable" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r789" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r790" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r790" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r788" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r788" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r791" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r789" ] }, "hypd_TreasurySharesRetired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "TreasurySharesRetired", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The value of treasury shares retired in noncash investing or financing transactions.", "label": "Treasury Shares Retired", "terseLabel": "Treasury shares retired" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r24" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Treasury stock balance at the end (in shares)", "periodStartLabel": "Treasury stock balance at the beginning (in shares)", "terseLabel": "Treasury stock, at cost, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r24" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury stock, at cost, 0 and 82,324 shares as of March 31, 2026 and December 31, 2025, respectively", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r24", "r25", "r42" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares withheld for employee payroll taxes (in shares)", "verboseLabel": "Shares were withheld for RSUs", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r5", "r39", "r60" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Shares withheld for employee payroll taxes", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r5", "r24", "r60" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHypeAssetUseServiceAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesHyperlendRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsNativeStakingDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesHyperlendPrivatePoolParticipationAgreementAndRevenueSharingAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r384" ] }, "hypd_UnderwritersOptionExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "UnderwritersOptionExercisePeriod", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails", "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time on underwriter's option exercise period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Underwriters Option Exercise Period", "terseLabel": "Option exercise period" } } }, "auth_ref": [] }, "us-gaap_UndistributedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UndistributedEarnings", "crdr": "credit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Undistributed Earnings, Basic", "terseLabel": "Net income (loss) attributable to participating securities", "totalLabel": "Net Income (Loss) Attributable to Participating Securities", "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed." } } }, "auth_ref": [ "r148", "r152" ] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "calculation": { "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedLabel": "Less: income allocated to preferred stockholders", "negatedTerseLabel": "Less: Net income allocated to preferred shareholders", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r148", "r151", "r152", "r275" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r785" ] }, "hypd_UsDollarPeggedStablecoinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "UsDollarPeggedStablecoinMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to US Dollar Pegged Stablecoin.", "label": "US Dollar Pegged Stablecoin [Member]", "terseLabel": "USDH Stablecoin" } } }, "auth_ref": [] }, "hypd_UsDollarPeggedStablecoinNativeToHyperliquidEcosystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "UsDollarPeggedStablecoinNativeToHyperliquidEcosystemMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsDigitalAssetReconciliationDetails", "http://www.eyenoviabio.com/role/DisclosureDigitalAssetsHyperionRyskVaultSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to US dollar pegged stablecoin native to Hyperliquid ecosystem.", "label": "US Dollar Pegged Stablecoin Native To Hyperliquid Ecosystem [Member]", "terseLabel": "Hyperliquid Ecosystem" } } }, "auth_ref": [] }, "hypd_UsTreasuryBillSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "UsTreasuryBillSecurities", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury bill.", "label": "US Treasury Bill Securities", "terseLabel": "US Treasury bill securities" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "UseOfEstimates", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r75", "r76", "r163", "r164", "r165", "r166", "r478", "r480", "r644" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r755" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantMember", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockCalculationOfWeightedAverageDilutiveSharesOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "verboseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r701", "r702", "r705", "r706", "r707", "r708" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDeficitSeriesPreferredStockSecuritiesPurchaseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Term of warrant", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r913", "r914", "r915" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding - diluted (in shares)", "verboseLabel": "Shares Outstanding - Diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r141", "r154" ] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Common shares issued", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r13", "r14" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Denominator (weighted average quantities):" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails", "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Denominator for basic net income (loss) per share (in shares)", "verboseLabel": "Shares Outstanding - Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r139", "r154" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "verboseLabel": "Shares Outstanding" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesRestrictedStock", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureNetIncomeLossPerShareOfCommonStockDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares, Restricted Stock", "terseLabel": "Add: vested unissued restricted stock units", "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends." } } }, "auth_ref": [ "r14" ] }, "hypd_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eyenoviabio.com/20260331", "localname": "WorkingCapitalDeficit", "crdr": "debit", "presentation": [ "http://www.eyenoviabio.com/role/DisclosureManagementSLiquidityPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of working capital, calculated as the difference between a company's current assets and current liabilities.", "label": "Working Capital Deficit", "terseLabel": "Working capital" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r753" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "65", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.FF.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481679/480-10-45-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479255/942-310-S50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.H.2.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478116/942-310-S99-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "181", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r798": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } }